Kapitalo Investimentos’s Adaptimmune Therapeutics ADAP Stock Holding History

Kapitalo Investimentos’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-36,400	Closed	-$53.1K	–	413
2022 Q4	$53.1K	Buy	+36,400	New	+$59K	0.04%	130

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Kapitalo Investimentos's ADAP Position: Q1 2023 in Review

Kapitalo Investimentos sold out of Adaptimmune Therapeutics (ADAP) in Q1 2023, closing a stake of 36,400 shares — an estimated $53.1K sold.

Kapitalo Investimentos first reported a position in ADAP in Q4 2022 and held it in 1 quarter. The position peaked at $53.1K in Q4 2022. 65 funds tracked by Wall St. Rank hold ADAP as of Q1 2023.

Kapitalo Investimentos reported no remaining Adaptimmune Therapeutics position as of Q1 2023 after selling out during the quarter.
Kapitalo Investimentos sold 36,400 Adaptimmune Therapeutics shares in Q1 2023, an estimated $53.1K.
Kapitalo Investimentos first reported a position in Adaptimmune Therapeutics in Q4 2022 and held it in 1 quarter.
Kapitalo Investimentos's Adaptimmune Therapeutics position peaked at $53.1K in Q4 2022.
65 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2023.

Based on Kapitalo Investimentos's 13F filing for Q1 2023, filed 29 Mar 2024.